Physician profile
Peter J Osterbauer
NPI 1831115955
$12,251.26
in general payments reported to CMS, 2019-2025
41 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $971 · 2020: $80.65 · 2021: $2,472 · 2022: $1,678 · 2023: $2,942 · 2024: $3,180 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,066 · Food and Beverage: $2,449 · Consulting Fee: $450 · Education: $83.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,066.22 |
| Food and Beverage | $2,449.19 |
| Consulting Fee | $450.00 |
| Education | $83.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $5,081.80 | 2019-2025 | Vns Therapy, Vns Therapy Sentiva Model 1000 Generator |
| Biogen, INC. | $2,278.61 | 2020-2025 | Tysabri, Vumerity, Leqembi |
| Emd Serono, INC. | $677.47 | 2019-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $551.79 | 2019-2024 | Ingrezza, Ongentys |
| Abbvie INC. | $483.89 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $256.08 | 2019 | |
| Jazz Pharmaceuticals INC. | $249.53 | 2021-2023 | Xywav |
| Alexion Pharmaceuticals, INC. | $240.74 | 2019-2025 | Ultomiris |
| Neurelis, INC. | $196.52 | 2021-2025 | Valtoco |
| Avadel Cns Pharmaceuticals, LLC | $172.70 | 2025 | Lumryz |
| Biohaven Pharmaceutical Holding Company Ltd. | $142.80 | 2022 | |
| Argenx US, INC. | $140.76 | 2022-2024 | Vyvgart Hytrulo |
| Ucb, INC. | $138.89 | 2022-2025 | Briviact, Nayzilam, Rystiggo |
| Tanabe Pharma America, INC. | $118.07 | 2023-2024 | |
| Genzyme Corporation | $115.34 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Osterbauer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.